EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
Zhen Qin(Chinese Academy of Sciences), Hongbin Ji(ShanghaiTech University), Hiroki Izumi(National Cancer Center Hospital East), Zhaoyuan Fang(Chinese Academy of Sciences), Meiting Yue(Chinese Academy of Sciences), Fengying Wu(Tongji University), Luonan Chen(ShanghaiTech University), Shengxiang Ren(Tongji University), Kwok‐Kin Wong(Brigham and Women's Hospital), Xinyuan Tong(Shanghai Jiao Tong University), Andrea Ventura(Memorial Sloan Kettering Cancer Center), Fei Li(Shanghai Medical College of Fudan University), Kōichi Goto(National Cancer Center Hospital East), Honghua Sun(Chinese Academy of Sciences), Shijie Tang(Chinese Academy of Sciences), Xiumin Yan(Shanghai Jiao Tong University), Susumu Kobayashi(Harvard University), Tetsuro Taki(National Cancer Center Hospital East), Yun Xue(Chinese Academy of Sciences), Yisheng Fang(Nanfang Hospital), Yijun Gao(Shanghai Institutes for Biological Sciences), Hsin‐Yi Huang(Center for Excellence in Molecular Cell Science), Yujuan Jin(Chinese Academy of Sciences), Xueliang Zhu(Shanghai Institutes for Biological Sciences), Liang Chen(Shanghai Jiao Tong University), Yuan Li(Fudan University Shanghai Cancer Center), Liang Hu(Chinese Academy of Sciences), Haiquan Chen(Shanghai Medical College of Fudan University), Yongchang Zhang(Central South University), Fuming Li(Fudan University), Wanying Wang(Tongji University), Shunta Mori(National Cancer Center Hospital East), Guoliang Xu(Chinese Academy of Sciences)
Cited by 21
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835